Wall Street analysts expect Aridis Pharmaceuticals Inc (NASDAQ:ARDS) to announce ($0.82) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Aridis Pharmaceuticals’ earnings. The company is scheduled to announce its next quarterly earnings report on Thursday, June 27th.
On average, analysts expect that Aridis Pharmaceuticals will report full year earnings of ($2.52) per share for the current year, with EPS estimates ranging from ($2.54) to ($2.50). For the next fiscal year, analysts anticipate that the firm will report earnings of ($4.05) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Aridis Pharmaceuticals.
Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.88. The firm had revenue of $1.39 million for the quarter, compared to the consensus estimate of $0.30 million.
NASDAQ:ARDS opened at $9.78 on Thursday. Aridis Pharmaceuticals has a twelve month low of $7.59 and a twelve month high of $13.85. The stock has a market capitalization of $77.45 million and a price-to-earnings ratio of -1.40.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.